Skip to main content
. Author manuscript; available in PMC: 2020 Jan 2.
Published in final edited form as: Circulation. 2019 Jan 2;139(1):24–36. doi: 10.1161/CIRCULATIONAHA.118.035640

Figure 3. Cardiovascular Disease Events Prevented and Treatment-Related SAEs Expected Per 1,000 Treated by Achieving and Maintaining 2017 ACC/AHA and JNC7 Guideline-Recommended SBP Goals Compared to Maintaining Current SBP Levels According to Treatment Groups.

Figure 3.

ACC: American College of Cardiology, AHA: American Heart Association, CVD: Cardiovascular disease, DM: Diabetes Mellitus, CKD: Chronic Kidney Disease, JNC7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JNC8PM: Eight Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, SBP: Systolic Blood Pressure, SAE: Serious Adverse Event.

Panels A and B show the number of cardiovascular disease events prevented per 1,000 individuals treated with achieving guideline-recommended blood pressure goals compared to current blood pressure levels for the 2017 ACC/AHA and the JNC7 guidelines within guideline-recommended treatment groups among those currently taking and not taking antihypertensive medication.

Panels C and D show the number of treatment-related SAEs expected with achieving guideline-recommended blood pressure goals compared to current blood pressure levels for the 2017 ACC/AHA and the JNC7 guidelines within guideline-recommended treatment groups among those currently taking and not taking antihypertensive medication.

The sub-groups presented represent different treatment target recommendations in the different guidelines. Cardiovascular disease events included stroke (fatal and nonfatal), coronary heart disease (fatal and nonfatal myocardial infarction or coronary heart disease death), or heart failure (fatal or non-fatal).

*Indicates a hypertension treatment group in which antihypertensive medication initiation of intensification is not recommended.

† Indicates treated uncontrolled groups where antihypertensive medication intensification is recommended. Due to lack of clinical-trial based evidence on incremental SAE risk in these groups, we assumed an additional SAE risk midway between the SAE risk with intensification to an intensive goal (<130/80 mmHg) and that of intensification to a <140/90 mmHg goal in treatment-naïve patients.